Fibroblast growth factor 18 clinical trials
Also written AS902330 and Sprifermin.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses fibroblast growth factor 18 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2013 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Merck KGaA, Darmstadt, Germany (3) · EMD Serono Research & Development Institute, Inc. (1) · EMD Serono (1)
Studies
Open first, then newest update. How each study uses fibroblast growth factor 18 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the KneeCompletedPhase 2EMD Serono Research & Development Institute, Inc.NCT01919164Written as SpriferminHow we know
- A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the KneeTerminatedPhase 2EMD SeronoNCT01689337Written as Sprifermin (AS902330)How we know
- Sprifermin (AS902330) in Cartilage Injury Repair (CIR)TerminatedPhase 2Merck KGaA, Darmstadt, GermanyNCT01066871Written as Sprifermin (AS902330) 10 mcgHow we know
- Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee ReplacementCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT00911469Written as AS902330How we know
- A Multicenter Study of rhFGF 18 in Patients With Knee Osteoarthritis Not Requiring SurgeryCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT01033994Written as AS902330How we know